Skip to main content
SpringerLink
Log in

Dexpramipexol ist bei der Behandlung der ALS nicht wirksam

Amyotrophe Lateralsklerose (ALS)

  • journal club
  • Published:
InFo Neurologie & Psychiatrie Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

1

Referenzen

  1. Danzeisen R et al. J Pharmacol Exp Ther 2006; 316: 189–99

    Article  CAS  PubMed  Google Scholar 

  2. Cudkowicz M et al. Nat Med 2011; 17: 1652–6

    Article  CAS  PubMed  Google Scholar 

  3. Cudkowicz ME, van den Berg LH, Shefner JM et al; EMPOWER investigators. Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial. Lancet Neurol 2013; 12: 1059–67

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für Neurologie an der Universität Ulm, Ulm, Deutschland

    Albert Ludolph (Ärztlicher Direktor)

Authors
  1. Albert Ludolph
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Albert Ludolph.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ludolph, A. Dexpramipexol ist bei der Behandlung der ALS nicht wirksam. InFo Neurologie 15, 32 (2013). https://doi.org/10.1007/s15005-013-0696-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15005-013-0696-z

Search

Navigation